Optimal management of clinical stage i testis cancer: One size does not fit all

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3477-3479

  De Wit, Ronald ^a   Bosl, George J ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HUMAN; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; SEMINOMA; SURVIVAL RATE; TUMOR VOLUME; HEALTH SURVEY; MALE; NOTE; PATHOLOGY; TESTIS TUMOR; WATCHFUL WAITING; TESTICULAR NEOPLASMS;

HUMANS; MALE; POPULATION SURVEILLANCE; TESTICULAR NEOPLASMS; WATCHFUL WAITING;

EID: 84891505479     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.0479     Document Type: Editorial

References (29)

1. Nichols CR, Roth B, Albers P, et al: Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 31:3490-3493, 2013
2. de Wit R, Fizazi K: Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24:5482-5492, 2006
3. Bosl GJ: Surveillance and survivorship in men with germ cell tumors: Should it change what the physician does? http://meetinglibrary.asco.org/sites/ meetinglibrary.asco.org/files/Educational%20Book/PDF%20Files/2010/ zds00110000182.pdf
4. Reference deleted
5. Van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006
6. Van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatmentspecific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
7. Haugnes HS, Bosl GJ, Boer H, et al: Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 30:3752- 3763, 2012
8. Schneider DT, Hilgenfeld E, Schwabe D, et al: Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 17:3226-3233, 1999
9. Yu HY, Madison RA, Setodji CM, et al: Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 27:4327-4332, 2009
10. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 23:2781-2788, 2005
11. Pettus JA, Carver BS, Masterson T, et al: Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 73:328-332, 2009
12. Kondagunta GV, Sheinfeld J, Mazumdar M, et al: Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22: 464-467, 2004
13. Stiggelbout AM, Kiebert GM, de Haes JC, et al: Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: A decision analysis. Eur J Cancer 32A:2267-2274, 1996
14. Warde P, Specht L, Horwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 20:4448-4452, 2002
15. Travis LB, Fossa SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005
16. Oliver RT, Mead GM, Rustin GJ, et al: A randomized trial of carboplatin versus radiotherapy for stage I seminoma: Mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 (ISRCTN 27163214). J Clin Oncol 29:957-962, 2011
17. Bosl GJ, Patil S: Carboplatin in clinical stage I seminoma: Too much and too little at the same time. J Clin Oncol 29:949-952, 2011
18. Aparicio J, Maroto P, del Muro XG, et. al: Risk-adapted treatment in clinical stage I testicular seminoma: The third Spanish Germ Cell Cancer Group study. J Clin Oncol 29:4677-4681, 2011
19. Powles T, Robinson D, Shamash J, et al: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443-447, 2008
20. Brenner DJ, Hall EJ: Computed tomography: An increasing source of radiation exposure. N Engl J Med 357:2277-2284, 2007
21. Rustin GJ, Mead GM, Stenning SP, et al: Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-The National Cancer Res Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25:1310-1315, 2007
22. de Wit R: Cutting back on computed tomography scan frequency in curative oncology: Get the picture. J Clin Oncol 25:1308-1309, 2007
23. Zondervan RL, Hahn PF, Sadow CA, et al: Body CT scanning in young adults: Examination indications, patient outcomes, and risk of radiation-induced cancer. Radiology 267:460-469, 2013
24. Pandharipande PV, Eisenberg JD, Lee RJ, et al: Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: The timing paradox. Radiology 266:896-904, 2013
25. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines: Testicular cancer, version 1, 2013.http://www.nccn.org/professionals/ physician-gls/pdf/testicular.pdf
26. Alomary I, Samant R, Gallant V: Treatment of stage I seminoma: A 15-year review. Urol Oncol 24:180-183, 2006
27. Cummins S, Yau T, Huddart R, et al: Surveillance in stage I seminoma patients: A long-term assessment. Eur Urol 57:673-678, 2010
28. Mortensen MS, Gundgaard MG, Lauritsen J, et al: A nationwide cohort study of surveillance for stage I seminoma. J Clin Oncol 31:284s, 2013 (suppl; abstr 4502)
29. Tanstad T, Smaland R, Klepp O, et al: Results from SWENOTECA V: A population-based protocol for seminomatous testicular cancer. J Clin Oncol 28:349s, 2010 (suppl; abstr 4531)